CRVS Stock — Corvus Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$12.56

Market cap

$1,056.6M

Cash

$411.5M

Enterprise value

$645.1M

Balance sheet

Cash	$411.5M
Debt	$0.0M
Net cash	$411.5M
Enterprise value	$645.1M
Basic shares	84.1M shares
Fully diluted shares	101.2M shares
Fully diluted market cap	$1,270.5M
Cash per share	$4.89

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CRVS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	Soquelitinib	Phase 2	Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema	—
Dec 13, 2027 - Jan 24, 2028	Soquelitinib	Phase 3	Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

soquelitinib

Phase 3 · Active

Aliases CPI-818

Target ITK (interleukin 2 inducible T cell kinase)

Partnerships Angel Pharmaceuticals (partner in China; conducting Phase 1b/2 trial in atopic dermatitis)

Indications

relapsed peripheral T-cell lymphoma (Phase 3)
atopic dermatitis (Phase 2)

Status note Lead product candidate. Enrolling a potentially registrational Phase 3 trial in relapsed peripheral T-cell lymphomas; randomized placebo-controlled Phase 2 in atopic dermatitis.

ciforadenant

Phase 1 · Active Modality: oral small molecule

Target A2A receptor (adenosine)

Partnerships Vernalis (R&D) Limited (exclusive worldwide license, Feb 2015; $3.0M milestone paid Feb 2017; tiered royalties)

Indications

metastatic renal cell cancer (1L, with ipilimumab + nivolumab) (Phase 1)

Status note A2A adenosine receptor antagonist. Being evaluated with the Kidney Cancer Research Consortium in an open-label Phase 1b/2 trial as first-line therapy for metastatic RCC in combination with ipilimumab and nivolumab.

mupadolimab

Phase 1 · Active Modality: monoclonal antibody

Target CD73

Indications

cancers and infectious diseases (broad) (Phase 1)

Status note Humanized monoclonal antibody targeting CD73. Company deferred initiating a potential Phase 2 randomized trial to prioritize soquelitinib and ciforadenant; remains in clinical development.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Soquelitinib
Lead indication	Peripheral T-Cell Lymphoma, Not Otherwise Specified
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06561048	Phase 3	Recruiting	Sponsor	CRVS	—	Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma	—
NCT07441395	Phase 2	Recruiting	Sponsor	CRVS	—	Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema	—
NCT03952078	Phase 1	Active, not recruiting	Sponsor	CRVS	—	T-cell Lymphoma	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Corvus Pharmaceuticals, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	7,165,006	no change	2.03%	2026-08-14
Braidwell LP	2,126,298	+373,500	1.18%	2026-08-14
Sphera Biotech	244,961	-3,000	0.52%	2026-08-14
ADAR1 Capital Management	117,101	+29,200	0.08%	2026-08-14
Logos Global Management	0	-450,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CRVS — Corvus Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders